SomnoMed (SOM) H1 2026 earnings summary

Executive summary

• Achieved record half-year revenue of AUD 60.7 million (13%–13.1% growth), driven by strong demand in Europe and North America, with net profit after tax of AUD 792,000 reversing a prior loss.

• EBITDA rose 35% to AUD 7.8 million, with margin improvement from 11% to 13% due to operating leverage and timing of investments.

• Positive operating cash flow of AUD 2.5 million after leases, with negative free cash flow of AUD 0.9 million reflecting planned capital expenditure.

• Manufacturing capacity increased by over 20%, improving turnaround times by more than 50% from June to December 2025.

• Key leadership appointments included a Chief Marketing Officer in North America and a Chief Transformation Officer.

Financial highlights

• Revenue grew 13%–13.1% to AUD 60.7 million, with gross margin stable at 61.3%.

• EBITDA increased to AUD 7.8 million from AUD 5.8 million, with margin rising to 13%.

• Net profit after tax was AUD 792,000, reversing a prior year loss.

• Capital expenditure was AUD 3.4 million, up from AUD 1.4 million, mainly for manufacturing and R&D.

• Cash balance increased to AUD 18 million at period end.

Outlook and guidance

• FY 2026 guidance reaffirmed: full-year revenue of AUD 119–126 million and EBITDA of AUD 10–12 million.

• Capital expenditure for FY 2026 expected to be AUD 6–8 million, focused on manufacturing expansion and R&D.

• Continued momentum anticipated in key markets, with disciplined cost control and targeted investment.

• FX assumptions for guidance reflect recent currency movements, especially USD and EUR.

• The company will continue to focus on producing and selling oral devices for sleep-related disorders globally.